Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EMBC NASDAQ:IRMD NASDAQ:PTHL NASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMBCEmbecta$9.96-2.0%$10.27$9.20▼$21.48$593.78M1.08522,700 shs673,486 shsIRMDiRadimed$66.17+13.4%$58.63$42.34▼$66.50$741.80M0.9440,089 shs108,444 shsPTHLPheton$0.81-8.9%$15.96$0.60▼$32.00$5.86MN/A3.43 million shs2.77 million shsSIBNSiBone$17.39+2.1%$17.90$11.70▼$20.05$725.72M0.91281,030 shs571,245 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMBCEmbecta-1.97%-15.09%-2.83%-21.76%-36.44%IRMDiRadimed+13.42%+17.49%+7.52%+23.75%+41.66%PTHLPheton-8.95%-97.22%-95.59%-80.10%+80,999,900.00%SIBNSiBone+2.11%+0.81%-5.64%+24.30%+14.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMBCEmbecta4.6531 of 5 stars3.23.03.30.02.73.33.8IRMDiRadimed4.1857 of 5 stars1.53.02.54.42.03.31.9PTHLPhetonN/AN/AN/AN/AN/AN/AN/AN/ASIBNSiBone3.9258 of 5 stars3.53.00.03.31.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMBCEmbecta 2.33Hold$19.0090.76% UpsideIRMDiRadimed 3.00Buy$72.008.81% UpsidePTHLPheton 0.00N/AN/AN/ASIBNSiBone 3.00Buy$22.5029.38% UpsideCurrent Analyst Ratings BreakdownLatest PTHL, SIBN, IRMD, and EMBC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$13.00 ➝ $12.005/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/6/2025SIBNSiBoneTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.005/6/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/6/2025SIBNSiBoneNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMBCEmbecta$1.08B0.54$3.27 per share3.05($12.80) per share-0.78IRMDiRadimed$73.24M11.49$1.79 per share36.87$6.85 per share9.66PTHLPheton$450K11.84N/AN/A$0.94 per share0.86SIBNSiBone$167.18M4.43N/AN/A$3.98 per share4.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMBCEmbecta$78.30M$0.9011.073.240.654.89%-19.67%12.27%8/8/2025 (Estimated)IRMDiRadimed$19.23M$1.5542.6933.09N/A26.33%23.28%20.59%N/APTHLPheton-$660KN/A0.00∞N/AN/AN/AN/AN/ASIBNSiBone-$30.91M-$0.64N/AN/AN/A-15.03%-16.00%-11.69%8/4/2025 (Estimated)Latest PTHL, SIBN, IRMD, and EMBC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q3 2025EMBCEmbecta$0.7720N/AN/AN/A$278.15 millionN/A8/4/2025Q2 2025SIBNSiBone-$0.19N/AN/AN/A$48.12 millionN/A8/1/2025Q2 2025IRMDiRadimed$0.45$0.45N/A$0.45$20.01 million$20.41 million5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/5/2025Q1 2025SIBNSiBone-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMBCEmbecta$0.606.02%N/A66.67%N/AIRMDiRadimed$0.681.03%N/A43.87%1 YearsPTHLPhetonN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ALatest PTHL, SIBN, IRMD, and EMBC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/1/2025IRMDiRadimedquarterly$0.171.13%8/18/20258/28/20255/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/20255/5/2025IRMDiRadimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMBCEmbectaN/A2.481.83IRMDiRadimedN/A8.877.62PTHLPhetonN/A12.3912.17SIBNSiBone0.218.537.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMBCEmbecta93.83%IRMDiRadimed92.34%PTHLPhetonN/ASIBNSiBone98.11%Insider OwnershipCompanyInsider OwnershipEMBCEmbecta0.42%IRMDiRadimed36.80%PTHLPhetonN/ASIBNSiBone4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMBCEmbecta2,10058.44 million58.20 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionablePTHLPheton116.58 millionN/AN/ASIBNSiBone35042.62 million40.91 millionOptionablePTHL, SIBN, IRMD, and EMBC HeadlinesRecent News About These CompaniesSI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025July 29, 2025 | globenewswire.comSiBone (SIBN) Projected to Post Quarterly Earnings on MondayJuly 28, 2025 | marketbeat.comVictory Capital Management Inc. Raises Stock Holdings in SiBone (NASDAQ:SIBN)July 25, 2025 | marketbeat.comLegato Capital Management LLC Acquires 36,649 Shares of SiBone (NASDAQ:SIBN)July 24, 2025 | marketbeat.comSI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025July 14, 2025 | globenewswire.comSiBone (NASDAQ:SIBN) Trading Down 3.9% - Time to Sell?July 11, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) Shares Sold by Brown Advisory Inc.July 9, 2025 | marketbeat.comInsider Selling: SiBone (NASDAQ:SIBN) CEO Sells 757 Shares of StockJuly 8, 2025 | insidertrades.comLaura Francis Sells 757 Shares of SiBone (NASDAQ:SIBN) StockJuly 7, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) SVP Michael A. Pisetsky Sells 3,127 SharesJuly 7, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) Insider Anthony J. Recupero Sells 3,310 SharesJuly 7, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 5,005 SharesJuly 7, 2025 | marketbeat.comAll You Need to Know About Si-Bone (SIBN) Rating Upgrade to BuyJuly 7, 2025 | zacks.comCalamos Advisors LLC Buys New Shares in SiBone (NASDAQ:SIBN)July 7, 2025 | marketbeat.comSI-BONE to Truist Securities MedTech Conference on June 17, 2025June 4, 2025 | globenewswire.comSI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025May 28, 2025 | globenewswire.comSI-BONE’s SWOT analysis: stock poised for growth amid market expansionMay 27, 2025 | investing.comWall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?May 26, 2025 | zacks.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 2,424 Shares of StockMay 21, 2025 | insidertrades.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 4,937 Shares of StockMay 16, 2025 | insidertrades.com4 Recent Earnings Winners Riding Fresh Momentum in May (SIBN)...May 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTHL, SIBN, IRMD, and EMBC Company DescriptionsEmbecta NASDAQ:EMBC$9.96 -0.20 (-1.97%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.06 +0.10 (+1.00%) As of 08/1/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.iRadimed NASDAQ:IRMD$66.17 +7.83 (+13.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$66.05 -0.12 (-0.18%) As of 08/1/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Pheton NASDAQ:PTHL$0.81 -0.08 (-8.95%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.82 +0.00 (+0.62%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.SiBone NASDAQ:SIBN$17.39 +0.36 (+2.11%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$17.38 -0.01 (-0.06%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
